Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Buys $27,173.58 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of NextCure stock in a transaction that occurred on Friday, October 23rd. The shares were bought at an average price of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the transaction, the insider owned 728,045 shares in the company, valued at $3,516,457.35. The trade was a 0.78% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, October 27th, Adar1 Capital Management, Llc purchased 3,553 shares of NextCure stock. The stock was bought at an average cost of $5.10 per share, for a total transaction of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc acquired 1,672 shares of NextCure stock. The stock was bought at an average price of $5.03 per share, with a total value of $8,410.16.
• On Friday, July 31st, Adar1 Capital Management, Llc acquired 36,303 shares of NextCure stock. The shares were bought at an average cost of $4.94 per share, with a total value of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The stock was purchased at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was purchased at an average price of $5.00 per share, for a total transaction of $17,050.00.

NextCure Stock Up 9.6%

Shares of NASDAQ NXTC traded up $0.50 during mid-day trading on Tuesday, hitting $5.72. The stock had a trading volume of 142,082 shares. NextCure, Inc. has a 1 year low of $1.55 and a 1 year high of $15.74. The business has a 50 day moving average price of $6.11 and a two-hundred day moving average price of $7.99.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85).

Institutional Investors Weigh In On NextCure

An institutional investor recently raised its stake in NextCure stock. Renaissance Technologies LLC lifted its stake in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,534 shares of the company’s stock after buying an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 42.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NXTC shares. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of NextCure in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.00.

About NextCure

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.